Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD ‘real world’ study
Abstract Introduction Chronic obstructive pulmonary disease (COPD) guidelines recommend reserving triple therapy of inhaled corticosteroid (ICS), long-acting β2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) for patients with exacerbations despite dual therapy. However, many patients re...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-05-01
|
| Series: | Respiratory Research |
| Online Access: | https://doi.org/10.1186/s12931-022-02037-2 |